Search

Search Results

• Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review

  Muhammad Hamza Dawood, Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Wilhelm Haverkamp

  2025-12-31

  https://doi.org/10.4081/cardio.2025.91

  935

  PDF: 410

  HTML: 60

• The scientific targets: the myocardium, the vasculature and the body’s response to heart failure

  Rafael Vidal-Pérez, Ewa A. Jankowska

  2024-03-28

  https://doi.org/10.4081/cardio.2024.19

  2926

  PDF: 319

  HTML: 25

• Sex differences in clinical characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction

  Christian Basile, Stefan D. Anker, Gianluigi Savarese

  2025-07-16

  https://doi.org/10.4081/cardio.2025.76

  993

  PDF: 291

  Supplementary: 203

  Appendix: 198

  HTML: 65

• Obesity and left atrial function: state of the art

  Ahmed Mustafa Rashid, Muhammad Shahzeb Khan, Fawaz Alenezi, Stefan D. Anker, Fabian Knebel

  2026-03-31

  https://doi.org/10.4081/cardio.2026.96

  904

  PDF: 312

  HTML: 123

• Sex-based differences in characteristics, management, and outcomes in heart failure with reduced ejection fraction

  Christian Basile, Stefan D. Anker, Gianluigi Savarese

  2025-06-30

  https://doi.org/10.4081/cardio.2025.73

  1074

  PDF: 366

  Supplementary: 203

  Appendix: 151

  HTML: 135

• Neck-to-height ratio in Bosnian university students according to the 2017 American College of Cardiology/American Heart Association guidelines on hypertension classification

  Asija Začiragić, Marija Mikić, Amela Dervišević, Orhan Lepara, Nesina Avdagić, Nermina Babić, Almir Fajkić, Amina Valjevac

  2024-03-28

  https://doi.org/10.4081/cardio.2024.27

  2152

  PDF: 392

  HTML: 16

• Beyond trial neutrality: treatment discontinuation and the hidden signal in SPIRIT-HF trial

  Viana Copeland, Andrew J.S. Coats

  2026-03-31

  https://doi.org/10.4081/cardio.2026.100

  1362

  PDF: 368

  HTML: 188

• Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial

  Markus S. Anker, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Lorenz Lehmann, Ulf Landmesser, Dominik P. Modest, Muhammad Shahzeb Khan, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Muhammad Sameer Arshad, Raluca Mincu, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Tienush Rassaf

  2025-08-20

  https://doi.org/10.4081/cardio.2025.78

  708

  PDF: 500

  Appendix: 259

  HTML: 72

• Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial

  Wolfram Doehner, Tim Friede, Frank Edelmann, Ulf Landmesser, Sebastian Winkler, Burkert Pieske, Fabian Knebel, Sebastian Kelle, Diethelm Tschöpe, Antje Meyer, Nadja Jauert, Marius Placzek, Jeanette Schulz-Menger, Stephan von Haehling, Stefan D. Anker

  2025-12-31

  https://doi.org/10.4081/cardio.2025.89

  446

  PDF: 155

  Appendix: 53

  HTML: 14

• Evolving targets for heart failure: the journey so far

  Giuseppe M.C. Rosano, Jerneja Farkas

  2023-11-28

  https://doi.org/10.4081/cardio.2023.6

  2382

  pdf: 456

  HTML: 4

• Mineralocorticoid receptor antagonists in heart failure with preserved (and mildly reduced) ejection fraction: a comparative review of spironolactone and finerenone

  Hafsa Azam, Syed Sarmad Javaid, Mahir Karakas

  2026-07-06

  https://doi.org/10.4081/cardio.2026.110

  57

  PDF: 22